# High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

> **NCT01704716** · PHASE3 · RECRUITING · sponsor: **St. Anna Kinderkrebsforschung** · enrollment: 3300 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Vincristine
- **DRUG:** Aldesleukin
- **DRUG:** ch14.18/CHO
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** G-CSF
- **DRUG:** Busulfan
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT01704716
- **Lead sponsor:** St. Anna Kinderkrebsforschung
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2002-02
- **Primary completion:** 2021-09-30
- **Final completion:** 2026-09
- **Target enrollment:** 3300 (ESTIMATED)
- **Last updated:** 2020-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01704716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01704716, "High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01704716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*